"Anthracyclines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
Descriptor ID |
D018943
|
MeSH Number(s) |
D02.455.426.559.847.562.050 D04.615.562.050 D09.408.051.059
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Anthracyclines".
Below are MeSH descriptors whose meaning is more specific than "Anthracyclines".
This graph shows the total number of publications written about "Anthracyclines" by people in this website by year, and whether "Anthracyclines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 1 | 0 | 1 |
2006 | 1 | 2 | 3 |
2007 | 2 | 0 | 2 |
2008 | 0 | 3 | 3 |
2010 | 0 | 1 | 1 |
2011 | 0 | 1 | 1 |
2017 | 0 | 1 | 1 |
2018 | 0 | 1 | 1 |
2019 | 0 | 2 | 2 |
2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anthracyclines" by people in Profiles.
-
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial. JAMA Oncol. 2020 Nov 01; 6(11):1778-1782.
-
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2020 01 01; 126(1):98-104.
-
Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clin Cancer Res. 2019 09 01; 25(17):5295-5300.
-
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. JAMA Oncol. 2018 09 01; 4(9):e180219.
-
Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 09; 146(3):531-537.
-
Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Immunity. 2013 Nov 14; 39(5):874-84.
-
Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. Acta Oncol. 2012 Apr; 51(4):550-4.
-
Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur J Cancer. 2011 Jan; 47(1):138-50.
-
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 2008 Nov; 6(10):1311-7.
-
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2009 May; 115(1):115-21.